10 results about "EGFR Gene Mutation" patented technology

The invention discloses a 2-amino-4-anilino pyrimidine compound as well as a preparation method and application of the 2-amino-4-anilino pyrimidine compound. The compound has a strong inhibition effect on EGFR (epidermal growth factor receptor) gene mutation targets and c-MET and has a strong inhibition effect on osimertinib drug-resistant cells; and the compound can inhibit proliferation of various tumor cells, and provides excellent application prospects for treatment of EGFR gene mutation and MET amplified malignant tumors.

The application belongs to the field of molecular biology, and particularly relates to a primer combination for detecting lung cancer EGFR mutant genes based on multiplex PCR-time of flight mass spectrometry and an application and a detection method. The primer combination is at least one EGFR mutant gene site in G719X (2155G>T, 2156G>C, 2155G>A), S768I (2303G>T), 19del (2236_2250del15, 2240_2257del18, 2235_2249del15), L858R (2573T>G), L861Q (2582T>A), T790M (2369C>T), 20ins (2300_2308dup, 2319_2320insCAC, 2310_2311insGGT). The application detects EGFR gene mutations by combining multiplex PCR and time of flight mass spectrometry, and has the advantages of low cost and fast detection speed compared with sequencing, fluorescent PCR and other technical means. The application further relates to an EGFR gene mutation detection kit.

Provided is a method for acquiring data on efficacy of a CDK4 / 6 inhibitor in a lung cancer cell, the method including detecting EGFR gene mutation, and CDKN2A / B gene deletion or loss-of-function mutation in a lung cancer cell derived from a lung cancer patient. Presence of EGFR gene mutation, and CDKN2A / B gene deletion or loss-of-function mutation indicates that the CDK4 / 6 inhibitor has efficacy.

An EGFR inhibitor is used for the treatment of EGFR gene mutation-positive lung cancer, but resistance is acquired over time, and the effect of the EGFR inhibitor disappears. There has been no effective measure against this.SOLUTION: A pharmaceutical composition for EGFR gene mutation-positive lung cancer, which comprises a first pharmaceutical composition for inhibiting EGFR and a second pharmaceutical composition for inhibiting at least one member selected from cGAS, STING and TBK1, and which can overcome resistance to EGFR inhibition and can be administered continuously while maintaining the effect of suppressing cell proliferation.SELECTED DRAWING: Figure 4

The invention provides a method for acquiring potency data of a CDK4 / 6 inhibitor in lung cancer cells. The method comprises the step of detecting EGFR gene mutation and CDKN2A / B gene deletion or function loss mutation in lung cancer cells from a lung cancer patient. The presence of EGFR gene mutation and CDKN2A / B gene deletion or loss of function indicates that the CDK4 / 6 inhibitor has efficacy.

The invention discloses a lung adenocarcinoma postoperative detection gene combination for recurrence risk assessment and application of the lung adenocarcinoma postoperative detection gene combination. The lung adenocarcinoma postoperative detection gene combination is composed of LOC283692, LOC644172, NAT8B, HIST1H1A, APEX2, CMSS1 and DYM. The lung adenocarcinoma is I-II stage lung adenocarcinoma with EGFR (epidermal growth factor receptor) gene mutation; the gene combination is used for constructing an LASSO scoring model for evaluating the postoperative recurrence risk of I-II stage lung adenocarcinoma patients with EGFR gene mutation. According to the method, accurate and quantitative risk division evaluation can be realized for I-II stage lung adenocarcinoma patients with EGFR gene mutation, and the method has the advantages of being simple, reliable and easy to popularize.

The application discloses a 2-amino-4-anilino pyrimidine compound and a preparation method and application thereof. The compound has a strong inhibiting effect on EGFR gene mutation targets and c-MET and has a strong inhibiting effect on osimertinib drug-resistant cells. Moreover, the compound can inhibit the proliferation of various tumor cells, and provides an excellent application prospect for the treatment of EGFR gene mutation and MET amplification malignant tumors.

The invention discloses a lung cancer CT (Computed Tomography) thin and thick layer image EGFR (Epidermal Growth Factor Receptor) gene mutation prediction device and method, and the device comprises a first processing module which is used for obtaining a lung cancer CT thin and thick layer image of a patient; the second processing module is used for performing data enhancement processing on the lung cancer CT thin and thick layer image; the third processing module is used for performing feature extraction on the lung cancer CT thin and thick layer image after data enhancement processing; the fourth processing module is used for carrying out orthogonal decomposition feature refinement and double loss optimization on the extracted features to obtain an EGFR gene mutation prediction model; and the fifth processing module is used for inputting the tested lung cancer CT thin and thick layer image into the EGFR gene mutation prediction model to carry out EGFR gene mutation detection. By adopting the technical scheme provided by the invention, the EGFR gene mutation state is accurately predicted, and an important decision basis is provided for targeted therapy and personalized diagnosis and treatment of lung cancer.

This invention discloses a reagent, kit, method, and application for detecting EGFR gene mutations. The reagent includes a primer set comprising a first primer pair for detecting the EGFR gene mutation site 19del, a second primer pair for detecting the EGFR gene mutation site T790M, and / or a third primer pair for detecting the EGFR gene mutation site L858R. The primer set and probes in this invention for detecting EGFR gene mutations exhibit high sensitivity and specificity, and show no cross-reactivity with wild-type samples, demonstrating promising application prospects.

The invention belongs to the technical field of biology, and particularly relates to a group of markers for predicting the immunotherapy effect of EGFR gene mutation NSCLC patients and application of the markers. The biomarker disclosed by the invention is simple and convenient to sample and quick in result reporting. The biomarker disclosed by the invention is high in accuracy: the AUC of CCL4 is equal to 0.771, the sensitivity is 0.64, the specificity is 0.67 ([95% CI: 0.62-0.93]); plt; 0.05) of the substrate (1); the AUC of the PD-L1 is equal to 0.720, the sensitivity is 0.60, the specificity is 0.82 ([95% CI: 0.55-0.89]); plt; 0.05) of the method. In a screening queue, a combined diagnosis ROC curve of CCL4 and PD-L1 is as follows: AUC is equal to 0.907, the sensitivity is 0.667, and the specificity is 1.000 ([95% CI: 0.696-1.000]); plt; 0.05) of the substrate (1); in the verification queue, the AUC of the combined diagnosis of CCL4 and PD-L1 is equal to 0.833, the sensitivity is 0.69, the specificity is 0.91, and the AUC is less than [95% CI: 0.70-0.96]; plt; 0.05) of the substrate (1); therefore, the efficiency of combined diagnosis of the CCL4 and the PD-L1 is higher than that of diagnosis by independently using the CCL4 or the PD-L1; the marker is high in diagnosis efficiency, the immunotherapy curative effect of the NSCLC patient with EGFR gene mutation is predicted, and clinical guidance is provided.